Intellia Therapeutics presented long‑term clinical data for its CRISPR‑based hereditary angioedema therapy lonvo‑z at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia. The four posters were shown during the conference, which ran from February 27 to March 2, 2026.
The pooled Phase 1/2 analysis of 32 patients showed a mean monthly attack rate of ≤0.2, a 96 % reduction from baseline, and 97 % of patients were attack‑free and free of long‑term prophylaxis at the data cutoff. The sustained decline in plasma kallikrein levels further supports the durability of the therapeutic effect.
Lonvo‑z carries orphan drug, RMAT, and PRIME designations, and Intellia plans to file a Biologics License Application in the second half of 2026, with a U.S. launch anticipated in the first half of 2027. The data reinforce the program’s potential to become a one‑time curative treatment for HAE.
John Leonard, Intellia’s President and CEO, said, “We expect the year ahead to be a pivotal one, highlighted by our topline Phase 3 data and planned BLA submission for lonvo‑z, which has the potential to transform the HAE treatment paradigm by freeing most patients from both their attacks and chronic therapy.”
Analysts have responded positively to the data. TD Cowen reiterated a “Buy” rating, citing lonvo‑z’s differentiation and undervaluation, while InvestingPro noted that five analysts had raised earnings estimates for the upcoming period in light of the program’s progress.
The presentation underscores lonvo‑z’s unique position as a one‑time, curative therapy in a market dominated by chronic treatments. The durable efficacy data, coupled with a clear regulatory and commercialization roadmap, strengthen Intellia’s competitive advantage and support a favorable outlook for the HAE program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.